Corcept Therapeutics received early FDA approval for Lyforli (relacorilant) combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant milestone. The company anticipates further growth from potential European approval, new cancer indications, and ongoing studies including a triple-combo with Avastin. Additionally, promising Phase 2 results for dazucorilant in ALS support a planned Phase 3 trial. Corcept raised its 2026 revenue forecast to $950–$1,050 million, driven by strong sales of Lyforli and Korlym, though risks remain from EU approval uncertainties and pricing pressures.
Bitcoin remained above $66,000 as U.S. Senate Republicans introduced an updated CLARITY Act draft restricting crypto sponsorship by senior officials until 2029. While Bitcoin and Ethereum ETFs saw net inflows, some meme coins like Shiba Inu and BONK ...
McDonald's Corporation offers a high-margin franchising model backed by prime real estate ownership, not just food sales. The stock trades at 21 times expected 2026 earnings, below its eight-year average, with a 2.8% dividend yield supported by stron...
Allegion reported strong second-quarter results, driven by broad growth in its Americas segment across residential and nonresidential markets, achieving a 30.1% adjusted operating margin. The company raised its full-year guidance, supported by a dura...
Shiba Inu's price surged 36% in a single day, adding about $1 billion to its market cap, driven mainly by $62 million in buying from South Korean traders on Upbit. This spike occurred without any new product launches or announcements, highlighting th...
Strategy claims its current capital structure can sustain interest payments and preferred stock dividends even if Bitcoin falls 11.4% annually for 5.8 years. The company holds 843,775 BTC and $3.225 billion in cash reserves to support obligations tot...
